Xeris Biopharma (XERS) Set to Release Quarterly Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS – Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.0317 per share and revenue of $101.68 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, analysts expect Xeris Biopharma to post $0.07 EPS for the current fiscal year and $0.30 EPS for the next fiscal year.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $10.64 on Thursday. Xeris Biopharma has a 1 year low of $5.25 and a 1 year high of $11.41. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -96.73 and a beta of 0.53. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The company’s 50 day simple moving average is $9.23 and its 200 day simple moving average is $7.48.

Wall Street Analysts Forecast Growth

XERS has been the topic of a number of research analyst reports. Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Barclays upped their price objective on Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 6th. Finally, Leerink Partners raised their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $13.20.

View Our Latest Stock Analysis on XERS

Insider Activity at Xeris Biopharma

In related news, insider Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00. Following the sale, the insider directly owned 1,599,208 shares of the company’s stock, valued at approximately $15,048,547.28. The trade was a 0.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total transaction of $47,050.00. Following the transaction, the insider owned 1,351,053 shares of the company’s stock, valued at approximately $12,713,408.73. This represents a 0.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 134,998 shares of company stock valued at $1,202,666. 4.35% of the stock is owned by insiders.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.

Read More

Earnings History for Xeris Biopharma (NASDAQ:XERS)

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.